[HTML][HTML] ISTH guidelines for antithrombotic treatment in COVID‐19
S Schulman, M Sholzberg, AC Spyropoulos… - Journal of Thrombosis …, 2022 - Elsevier
Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with
coronavirus disease 2019 (COVID‐19) may realize additional benefits from heparins …
coronavirus disease 2019 (COVID‐19) may realize additional benefits from heparins …
[HTML][HTML] Prophylactic-dose direct oral anticoagulants for non-hospitalised people with COVID-19: A meta-analysis of randomised controlled trials
Q Song, H Liu, H Tan, B Yang, H Zhang… - Journal of Global …, 2024 - ncbi.nlm.nih.gov
Background Several reviews have been conducted on thromboprophylaxis in non-
hospitalised patients with coronavirus disease 2019 (COVID-19). In this systematic review …
hospitalised patients with coronavirus disease 2019 (COVID-19). In this systematic review …
Tromboprofilaxis en COVID-19. Nuevas evidencias
R Ferrandis, P Sierra, A Gomez-Luque - Revista Española de …, 2023 - Elsevier
Recientes publicaciones han puesto en duda la eficacia de la utilización de dosis
terapéuticas o intermedias de heparina de bajo peso molecular (HBPM) en pacientes …
terapéuticas o intermedias de heparina de bajo peso molecular (HBPM) en pacientes …
Dicoumarol is an effective post-exposure prophylactic for SARS-CoV-2 Omicron infection in human airway epithelium
Y Peng, S Chen, Z Wang, Z Zhou, J Sun… - … and Targeted Therapy, 2023 - nature.com
Repurposing existing drugs to inhibit SARS-CoV-2 infection in airway epithelial cells (AECs)
is a quick way to find novel treatments for COVID-19. Computational screening has found …
is a quick way to find novel treatments for COVID-19. Computational screening has found …
Treatment with prophylactic oral anticoagulants and the risk of mortality in COVID-19 patients: a nationwide cohort study
S Altaraihi, P Kamstrup, J Eklöf… - ERJ Open …, 2023 - Eur Respiratory Soc
Background Venous thromboembolism has been reported in patients with coronavirus
disease 2019 (COVID-19). It remains unclear if premorbid use of prophylactic oral …
disease 2019 (COVID-19). It remains unclear if premorbid use of prophylactic oral …
COVID-19 thromboprophylaxis. New evidence
R Ferrandis, P Sierra, A Gomez-Luque - Revista Española de …, 2023 - Elsevier
Recent publications have questioned the efficacy of using therapeutic or intermediate doses
of low molecular weight heparin in COVID-19 patients, especially in the most severe …
of low molecular weight heparin in COVID-19 patients, especially in the most severe …
Assessment of the Hemostatic Activity of" Hemoben" in the Model of Liver Damage on Hypocoagulation
SI Ismailov, AK Babadjanov, DS Khodzhiev… - International Journal of … - neliti.com
In the article, the authors present the results of experimental studies on the hemostatic
properties assessment of the new domestic hemostatic implant Hemoben under artificial …
properties assessment of the new domestic hemostatic implant Hemoben under artificial …